Short answer
Vertex Pharmaceuticals (VRTX) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3.0B (up 7.8% year over year) with net income of $1.0B.
Q1 2026 key financials · XBRL
- Revenue
- $3.0B
- +7.8% YoY
- Net income
- $1.0B
- +59.6% YoY
- Operating margin
- 38.1%
- EPS (diluted)
- $4.02
- +61.4% YoY
Source: XBRL data from the Vertex Pharmaceuticals (VRTX) Q1 2026 10-Q on SEC EDGAR. USD.
Vertex Pharmaceuticals Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Risk factors not provided; excerpt begins with forward-looking-statement language and Items 2, 5, and 6
- Share repurchase authorization $4.0 billion, with $3.04 billion remaining at March 31, 2026
- 741,135 shares repurchased during the quarter at average $464.79 per share
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vertex Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.